(Q33423800)

English

Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

26 July 2017

Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial (English)

1 reference

Europe PubMed Central

26 July 2017

phase III clinical trial

0 references

0 references

multicenter clinical trial

0 references

hepatocellular carcinoma

1 reference

based on heuristic

inferred from title

object named as

Masatoshi Kudo

20

0 references

Hyun Cheol Chung

object named as

Hyun Cheol Chung

8

0 references

object named as

Ian Chau

15

0 references

author name string

Andrew X Zhu

1

1 reference

Europe PubMed Central

26 July 2017

Joon Oh Park

2

1 reference

Europe PubMed Central

26 July 2017

Baek-Yeol Ryoo

3

1 reference

Europe PubMed Central

26 July 2017

Chia-Jui Yen

4

1 reference

Europe PubMed Central

26 July 2017

Ronnie Poon

5

1 reference

Europe PubMed Central

26 July 2017

Davide Pastorelli

6

1 reference

Europe PubMed Central

26 July 2017

Jean-Frederic Blanc

7

1 reference

Europe PubMed Central

26 July 2017

Ari D Baron

9

1 reference

Europe PubMed Central

26 July 2017

Tulio Eduardo Flesch Pfiffer

10

1 reference

Europe PubMed Central

26 July 2017

Takuji Okusaka

11

1 reference

Europe PubMed Central

26 July 2017

Katerina Kubackova

12

1 reference

Europe PubMed Central

26 July 2017

Jorg Trojan

13

1 reference

Europe PubMed Central

26 July 2017

Javier Sastre

14

1 reference

Europe PubMed Central

26 July 2017

Shao-Chun Chang

16

1 reference

Europe PubMed Central

26 July 2017

Paolo B Abada

17

1 reference

Europe PubMed Central

26 July 2017

Ling Yang

18

1 reference

Europe PubMed Central

26 July 2017

Jonathan D Schwartz

19

1 reference

Europe PubMed Central

26 July 2017

REACH Trial Investigators

21

1 reference

Europe PubMed Central

26 July 2017

publication date

18 June 2015

1 reference

Europe PubMed Central

26 July 2017

Lancet Oncology Commission

1 reference

Europe PubMed Central

26 July 2017

16

1 reference

Europe PubMed Central

26 July 2017

7

1 reference

Europe PubMed Central

26 July 2017

859-870

1 reference

Europe PubMed Central

26 July 2017

Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900050-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Long interval between HCV infection and development of hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900050-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Diagnosis of hepatocellular carcinoma.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900050-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Staging systems in hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900050-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Sorafenib in advanced hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900050-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900050-9

7 January 2021

based on heuristic

inferred from DOI database lookup

GIDEON (Global Investigation of therapeutic DEcisions in hepatocellular carcinoma and Of its treatment with sorafeNib): second interim analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900050-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Hepatocellular carcinoma: reasons for phase III failure and novel perspectives on trial design

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900050-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Brivanib and FOLFOX in hepatocellular carcinoma: finding the common themes among negative trials

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900050-9

7 January 2021

based on heuristic

inferred from DOI database lookup

The VEGF family in cancer and antibody-based strategies for their inhibition

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900050-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Vascular endothelial growth factors and receptors: anti-angiogenic therapy in the treatment of cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900050-9

7 January 2021

based on heuristic

inferred from DOI database lookup

The critical role of vascular endothelial growth factor in tumor angiogenesis

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900050-9

7 January 2021

based on heuristic

inferred from DOI database lookup

HCC and angiogenesis: possible targets and future directions

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900050-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase I pharmacologic and biologic study of ramucirumab (IMC-1121B), a fully human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900050-9

7 January 2021

based on heuristic

inferred from DOI database lookup

A phase II and biomarker study of ramucirumab, a human monoclonal antibody targeting the VEGF receptor-2, as first-line monotherapy in patients with advanced hepatocellular cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900050-9

7 January 2021

based on heuristic

inferred from DOI database lookup

A phase 2, single-arm study of ramucirumab in patients with metastatic renal cell carcinoma with disease progression on or intolerance to tyrosine kinase inhibitor therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900050-9

7 January 2021

based on heuristic

inferred from DOI database lookup

The use of single-agent sorafenib in the treatment of advanced hepatocellular carcinoma patients with underlying Child-Pugh B liver cirrhosis: a retrospective analysis of efficacy, safety, and survival benefits

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900050-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Sorafenib for hepatocellular carcinoma according to Child-Pugh class of liver function

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900050-9

7 January 2021

based on heuristic

inferred from DOI database lookup

A new prognostic system for hepatocellular carcinoma: A retrospective study of 435 patients

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900050-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Clinical characteristics and prognosis of hepatocellular carcinoma: analysis based on serum alpha-fetoprotein levels

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900050-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Prognostic factors after liver resection for hepatocellular carcinoma with hepatitis B virus-related cirrhosis: surgeon's role in survival

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900050-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Evaluation of absolute serum α-fetoprotein levels in liver transplant for hepatocellular cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900050-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Integrative transcriptome analysis reveals common molecular subclasses of human hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900050-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Angiogenesis and clinicopathologic characteristics in different hepatocellular carcinoma subtypes defined by EpCAM and α-fetoprotein expression status

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900050-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Prognostic significance and potential therapeutic target of VEGFR2 in hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900050-9

7 January 2021

based on heuristic

inferred from DOI database lookup

EpCAM and alpha-fetoprotein expression defines novel prognostic subtypes of hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900050-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Postprogression survival of patients with advanced hepatocellular carcinoma: rationale for second-line trial design

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900050-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Predictors of survival in patients with advanced hepatocellular carcinoma who permanently discontinued sorafenib.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900050-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900050-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S1470-2045(15)00050-9

1 reference

Europe PubMed Central

26 July 2017

1 reference

Europe PubMed Central

26 July 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33423800&oldid=1894918938"